Skip to main content

Nyxoah SA

corporate_fare Company Profile

Nyxoah SA

NYXH·NASDAQ·Industrial Applications And Services·CIK 0001857190

Nyxoah SA is a medical technology company that develops and commercializes solutions for Obstructive Sleep Apnea (OSA). The company's primary product is the Genio system, a hypoglossal neurostimulation (HGNS) therapy designed for moderate to severe OSA. This system is implanted through a single-incision procedure and is CE-Marked and FDA approved. OSA is a common sleep-disordered breathing condition linked to increased mortality risk and conditions such as cardiovascular diseases, depression, and stroke. The Genio system is a HGNS device that treats OSA by providing bilateral stimulation to maintain upper airway patency, reducing obstructive breathing events during sleep. Nyxoah SA began generating revenue from Genio system sales in Europe in July 2020. On August 8, 2025, the FDA approved the Genio system for adult patients with moderate to severe OSA, specifically those with an Apnea-Hypopnea Index (AHI) of greater than or equal to 15 and less than or equal to 65. Sales of the Genio system in the U.S. commenced in September 2025. Approximately 425 million people globally between the ages of 30 and 69 suffer from moderate to severe OSA. In Nyxoah SA's initial target markets in Europe, an estimated 23.8 million individuals have moderate to severe OSA.

Nyxoah SA (NASDAQ:NYXH) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 19 items for NYXH at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-09-29, rated 7/10. Across its 19 most recent items scored 7 or higher, the top rating is 9/10, with 17 rated 8 or above. Recent SEC coverage for NYXH spans 6-K, 424B5, FWP, 20-F.

Recent high-impact activity:

  • Nyxoah Taps Former Teleflex CEO Liam Kelly to Lead Next Phase
  • Nyxoah Delivers €7.7M in Preliminary Q2 Revenue as CMS Proposes 12–15% Reimbursement Boost
  • Nyxoah Secures $15M EIB Loan, Major Shareholders Boost Stakes Post-$95M Offering
  • Nyxoah's Genio® Wins Prestigious Prix Galien UK 2026 Award for Best Medical Technology
  • Nyxoah Confirms Issuance of 55.2M Shares, Doubling Outstanding Count Post-$95M Offering

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$90.08M
Diluted EPS
-$2.36
Op. Cash Flow
-$68.98M
Free Cash Flow
-$69.78M
Gross Profit
$6.33M
Operating Income
-$83.48M
Cash & Equivalents
$7.87M
Debt / Equity
0.00×
Shares Outstanding
43.03M sh
Source: 20-F · filed 2026-03-26 · accession 0001104659-26-035161

Short Interest & Short Volume

1.00 days to cover

FINRA reported short interest of 269,141 shares in NYXH as of the September 15, 2026 settlement, a 10.2% increase from the prior period — about 1.0 days to cover at its recent average daily volume. On October 2, 2026, 60.5% of NYXH volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)269,141 shares as of September 15, 2026
Change vs prior period▲ 10.2%
Days to cover1.00 at avg daily volume of 958,977
Daily short volume (FINRA facilities)60.5% of 25,150 shares on October 2, 2026
5-day average short volume43.7%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Low risk

Filing-implied dilution signals for NYXH, detected from its recent SEC filings · based on capital-structure filings through 2026-06-11.

1 recent capital raise

Public Offering Finalized · Significant Dilution

⚠ A more recent filing has been published for this ticker since this signal was computed; it may not yet be reflected — see the filings below.

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Insider Transactions

NYXH files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.

Browse all tickers starting with N →
$1.36
52-week range · as of 2026-09-29 $1.26 – $6.87
Market cap
$138.5M
Volume
68.6K (0.2× avg)
3-mo avg 444.5K
Live data · 2026-10-03 19:03 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed NYXH - Latest Insights

NYXH
Sep 29, 2026, 4:05 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $1.37
Real-time Price: $1.36 info
Change: -$0.010 (-0.73%) info
Market Cap: $138.503M info
NYXH
Jul 09, 2026, 4:30 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $1.67
Real-time Price: $1.36 info
Change: -$0.310 (-19%) info
Market Cap: $138.503M info
NYXH
Jun 23, 2026, 4:05 PM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $1.57
Real-time Price: $1.36 info
Change: -$0.210 (-13%) info
Market Cap: $138.503M info
NYXH
Jun 15, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.55
Real-time Price: $1.36 info
Change: -$0.190 (-12%) info
Market Cap: $138.503M info
NYXH
Jun 11, 2026, 5:00 PM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $1.48
Real-time Price: $1.36 info
Change: -$0.120 (-8%) info
Market Cap: $138.503M info
NYXH
Jun 10, 2026, 4:30 PM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $1.30
Real-time Price: $1.36 info
Change: +$0.060 (+5%) info
Market Cap: $138.503M info
NYXH
Jun 10, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $1.31
Real-time Price: $1.36 info
Change: +$0.050 (+4%) info
Market Cap: $138.503M info
NYXH
Jun 08, 2026, 8:00 AM EDT
Filing Type: 424B5
Importance Score:
9
Price at Filing: $1.70
Real-time Price: $1.36 info
Change: -$0.340 (-20%) info
Market Cap: $138.503M info
NYXH
Jun 05, 2026, 3:53 PM EDT
Filing Type: FWP
Importance Score:
9
Price at Filing: $1.46
Real-time Price: $1.36 info
Change: -$0.100 (-7%) info
Market Cap: $138.503M info
NYXH
Jun 05, 2026, 11:25 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $1.58
Real-time Price: $1.36 info
Change: -$0.2186 (-14%) info
Market Cap: $138.503M info
NYXH
Jun 04, 2026, 4:10 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $2.47
Real-time Price: $1.36 info
Change: -$1.11 (-45%) info
Market Cap: $138.503M info
NYXH
Jun 04, 2026, 4:07 PM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $2.47
Real-time Price: $1.36 info
Change: -$1.11 (-45%) info
Market Cap: $138.503M info
NYXH
Jun 04, 2026, 4:02 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $2.47
Real-time Price: $1.36 info
Change: -$1.11 (-45%) info
Market Cap: $138.503M info
NYXH
May 12, 2026, 4:09 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $3.07
Real-time Price: $1.36 info
Change: -$1.71 (-56%) info
Market Cap: $138.503M info
NYXH
Mar 26, 2026, 4:01 PM EDT
Filing Type: 20-F
Importance Score:
9
Price at Filing: $3.09
Real-time Price: $1.36 info
Change: -$1.73 (-56%) info
Market Cap: $138.503M info
NYXH
Mar 19, 2026, 5:04 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $3.17
Real-time Price: $1.36 info
Change: -$1.81 (-57%) info
Market Cap: $138.503M info
NYXH
Mar 19, 2026, 4:10 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $3.17
Real-time Price: $1.36 info
Change: -$1.81 (-57%) info
Market Cap: $138.503M info
NYXH
Jan 30, 2026, 5:15 PM EST
Filing Type: 6-K
Importance Score:
8
Price at Filing: $4.75
Real-time Price: $1.36 info
Change: -$3.39 (-71%) info
Market Cap: $138.503M info
NYXH
Jan 14, 2026, 4:05 PM EST
Filing Type: 6-K
Importance Score:
8
Price at Filing: $5.12
Real-time Price: $1.36 info
Change: -$3.76 (-73%) info
Market Cap: $138.503M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets